Core Insights - Procter & Gamble (PG) reported revenue of $20.89 billion for the quarter ended June 2025, marking a year-over-year increase of 1.7% and exceeding the Zacks Consensus Estimate by 0.39% [1] - The earnings per share (EPS) for the same period was $1.48, up from $1.40 a year ago, representing a surprise of 3.5% over the consensus estimate of $1.43 [1] Financial Performance Metrics - Organic Sales Growth for Beauty was 1%, below the average estimate of 1.7% [4] - Organic Sales Growth for Grooming was 1%, compared to the estimated 2.8% [4] - Total Organic Sales Growth for P&G was 2%, exceeding the average estimate of 1.4% [4] - Organic Sales Growth for Baby, Feminine & Family Care was 1%, above the estimate of 0.6% [4] - Organic Sales Growth for Fabric & Home Care was 1%, slightly below the estimate of 1.4% [4] - Organic Sales Growth for Health Care was 2%, below the average estimate of 3.1% [4] Net Sales Performance - Net sales for Beauty were $3.73 billion, slightly below the estimate of $3.76 billion, with a year-over-year change of +0.2% [4] - Net sales for Grooming were $1.68 billion, matching the average estimate, with a year-over-year increase of +1.6% [4] - Net sales for Corporate were $274 million, significantly above the estimate of $186.14 million, representing a +35.6% change year-over-year [4] - Net sales for Fabric & Home Care were $7.39 billion, slightly above the estimate of $7.36 billion, with a year-over-year change of +1.7% [4] - Net sales for Baby, Feminine & Family Care were $5.09 billion, exceeding the estimate of $5.02 billion, with a year-over-year change of +1.7% [4] - Net sales for Health Care were $2.72 billion, slightly below the estimate of $2.74 billion, with a year-over-year change of +1.8% [4] Stock Performance - P&G shares have returned -1.4% over the past month, while the Zacks S&P 500 composite has increased by +3.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

MEXICO CITY, July 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter of 2025. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.Comments from Genomma's CEO, Marco Sparvieri"Genomma's second quarter sales grew +0.5%, or +5.5% excluding Argentina, reflecting a significant ...

Core Insights - 3M reported revenue of $6.16 billion for the quarter ended June 2025, a year-over-year decline of 1.6%, with an EPS of $2.16 compared to $1.93 a year ago, exceeding the Zacks Consensus Estimate of $6.12 billion by 0.67% and delivering an EPS surprise of 7.46% [1] Group 1: Financial Performance - Revenue for Safety and Industrial segment was $2.86 billion, surpassing the two-analyst average estimate of $2.78 billion, reflecting a year-over-year increase of 3.6% [4] - Corporate and Unallocated segment net sales reached $87 million, slightly above the $85 million average estimate, marking a year-over-year change of 1.2% [4] - Consumer segment net sales were reported at $1.27 billion, matching the average estimate and showing a 0.6% increase compared to the previous year [4] Group 2: Operating Income - Non-GAAP operating income for the Consumer segment was $268 million, exceeding the average estimate of $264.25 million [4] - Non-GAAP operating income for Transportation and Electronics was $479 million, above the estimated $465.99 million [4] - Non-GAAP operating income for Safety and Industrial was $738 million, slightly higher than the average estimate of $730.6 million [4] Group 3: Stock Performance - 3M shares returned 11.6% over the past month, outperforming the Zacks S&P 500 composite's 5.4% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

TULIKIVI CORPORATION INTERIM REPORT 9 MAY 2025 AT 1 PM - The Tulikivi Group’s first-quarter net sales were EUR 6.0 million (EUR 8.5 million, 1–3/2024).- The Tulikivi Group’s first-quarter operating profit was EUR -0.7 (0.3) million and the profit before taxes was EUR -0.9 (0.1) million.- The equity ratio at the end of the review period was 49.4 per cent (49.5).- Order books stood at EUR 4.3 (5.4) million at the end of the review period.- The environmental permit process for the Suomussalmi talc project is m ...

Core Insights - Techne (TECH) reported revenue of $316.18 million for the quarter ended March 2025, reflecting a year-over-year increase of 4.2% and surpassing the Zacks Consensus Estimate by 0.30% [1] - The company's EPS was $0.56, up from $0.48 in the same quarter last year, resulting in an EPS surprise of 9.80% compared to the consensus estimate of $0.51 [1] Financial Performance - Organic Growth was reported at 6%, exceeding the average estimate of 5.2% from three analysts [4] - Organic Growth in Diagnostics and Genomics was 2%, below the two-analyst average estimate of 6.2% [4] - Organic Growth in Protein Sciences was 7%, significantly higher than the average estimate of 2.8% from two analysts [4] - Net Sales from intersegment revenue was -$0.74 million, worse than the average estimate of -$0.55 million, representing a year-over-year decline of 3.7% [4] - Net Sales in Protein Sciences reached $227.69 million, surpassing the average estimate of $224.75 million, with a year-over-year increase of 6.1% [4] - Net Sales in Diagnostics and Genomics were $89.23 million, slightly below the average estimate of $92.50 million, showing a year-over-year growth of 2% [4] Market Performance - Techne's shares have returned -2.2% over the past month, contrasting with the Zacks S&P 500 composite's increase of 10.6% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Viewpoint - Otis Worldwide reported mixed results for Q4 2024, with adjusted earnings missing estimates while net sales exceeded expectations, marking the second consecutive earnings miss after a strong performance in prior quarters [2][5]. Financial Performance - Adjusted earnings were 93 cents per share, missing the Zacks Consensus Estimate of 95 cents by 2.1%, but increased 6.9% year-over-year from 87 cents [5]. - Net sales reached $3.68 billion, slightly above the consensus mark of $3.65 billion, reflecting a 1.5% year-over-year growth, with organic sales increasing by 1.9% [5]. - Adjusted operating margin expanded by 30 basis points to 15.9%, driven by favorable performance in the Service segment [6]. Segment Analysis - **New Equipment Segment**: - Net sales were $1.36 billion, down 7.4% year-over-year, with organic sales declining 6.8% [7]. - Orders decreased by 4% at constant currency, with significant declines in China and EMEA [8]. - Operating margin contracted by 140 basis points to 4.7% due to lower volume and unfavorable mix [9]. - **Service Segment**: - Net sales increased by 7.6% year-over-year to $2.32 billion, supported by a 7.8% rise in organic sales [10]. - Operating margin improved by 50 basis points to 24.5%, aided by higher volume and favorable pricing [11]. Annual Highlights - For 2024, Otis Worldwide reported annual revenues of $14.26 billion, a 0.4% increase from $14.21 billion in 2023, with adjusted EPS rising to $3.83 from $3.54 [12]. - Adjusted operating margin for the year expanded by 50 basis points to 16.5% [12]. Financial Position - As of December 31, 2024, cash and cash equivalents were $2.3 billion, up from $1.27 billion at the end of 2023, while long-term debt increased to $6.97 billion [13]. - Net cash flows from operating activities were $1.56 billion, down from $1.63 billion a year ago, with adjusted free cash flow totaling $1.57 billion [13]. 2025 Outlook - Otis expects net sales between $14.1 billion and $14.4 billion, with organic sales growth projected between 2% and 4% [14]. - Adjusted EPS is anticipated to be between $4 and $4.10, indicating a year-over-year growth of 4-7% [15]. Estimate Trends - There has been a downward trend in estimates, with the consensus estimate shifting down by 5.23% [16]. VGM Scores - Otis Worldwide has a Growth Score of A but lags in Momentum with an F, resulting in an aggregate VGM Score of C [17].